Olaparib (new indication: high risk early breast cancer with BRCA1/2-mutations and HER2-negative as monotherapy or in combination with endocrine therapy for the adjuvant treatment of previously treated patients)



  • Active Sustance: Olaparib
  • Name: Lynparza®
  • Therapeutic area: Breast cancer
  • Pharmaceutical company: AstraZeneca GmbH


Time table:

  • Start: 01.09.2022
  • Final decision by G-BA: 16.02.2023


Final decision:

  • Indication for a minor additional benefit